Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A JBI Centre of Excellence, Halifax, NS, Canada.
JBI Evid Synth. 2021 Jan;19(1):242-250. doi: 10.11124/JBISRIR-D-19-00420.
The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking benzodiazepine receptor agonists.
Benzodiazepines and Z-drugs are widely prescribed for the treatment of anxiety disorders and insomnia even though they are not recommended as an initial treatment for these indications. Benzodiazepine and Z-drug use is associated with an elevated risk of traffic accidents, and guidance documents instruct patients to consult with their health care providers for instructions on how to safely operate a motor vehicle while consuming these medications. However, little is known about the assessments that measure driving performance regarding the extent and length of impairment from the consumption of the individual benzodiazepines and Z-drugs.
Eligible studies will include participants who are new, intermittent, or chronic users of benzodiazepines and Z-drugs. No exclusions will be applied regarding the health status of participants or whether their benzodiazepine and Z-drug use is for an approved indication as indicated by government agencies (eg, Health Canada) or practice guidelines. Studies that examine the consumption of a benzodiazepine and Z-drug in association with the operation of a motor vehicle (real or simulated) with direct or indirect objective or standard subjective measures or indicators of impairment while operating a motor vehicle will be considered.
Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) will be searched as sources of published studies. Only studies published in English will be included, and there will be no limit on dates of publication. After screening the titles and abstracts of identified citations, two independent reviewers will retrieve potentially relevant full-text studies and extract data. Data will be presented in diagrammatic or tabular form accompanied by a narrative summary.
本范围综述的目的是确定、绘制和描述用于评估苯二氮䓬受体激动剂使用者驾驶表现的评估工具的证据。
苯二氮䓬类和 Z 类药物广泛用于治疗焦虑症和失眠症，尽管它们不被推荐作为这些适应症的初始治疗药物。苯二氮䓬类和 Z 类药物的使用与交通事故风险增加有关，并且指导文件指示患者咨询他们的医疗保健提供者，以获取有关如何在使用这些药物时安全操作机动车辆的说明。然而，对于个体苯二氮䓬类和 Z 类药物使用导致的驾驶表现损害的程度和持续时间，人们对评估工具知之甚少。
合格的研究将包括新、间歇性或慢性使用苯二氮䓬类和 Z 类药物的参与者。不排除参与者的健康状况，也不排除他们的苯二氮䓬类和 Z 类药物使用是否符合政府机构（例如加拿大卫生部）或实践指南所规定的批准适应症。将研究在驾驶机动车辆（真实或模拟）时同时使用苯二氮䓬类和 Z 类药物的情况，使用直接或间接的客观或标准的主观测量或驾驶表现受损的指标进行评估的研究。
将从 Embase（Elsevier）、MEDLINE（Ovid）和 PsycINFO（EBSCO）中搜索已发表的研究作为研究来源。仅包括以英文发表的研究，且对发表日期不设限制。在筛选确定的引用的标题和摘要后，两名独立的审查员将检索可能相关的全文研究并提取数据。将以图表或表格形式呈现数据，并附有叙述性摘要。
